tadalafil has been researched along with cyclin d1 in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abadi, AH; Chang, WC; Chen, X; Clapper, ML; Gary, BD; Grizzle, WE; Gurpinar, E; Keeton, AB; Li, N; Li, Y; Moyer, MP; Piazza, GA; Tinsley, HN; Xi, Y; Zhu, B | 1 |
1 other study(ies) available for tadalafil and cyclin d1
| Article | Year |
|---|---|
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Carbolines; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclin D1; HCT116 Cells; HT29 Cells; Humans; Inhibitor of Apoptosis Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Sulindac; Survivin; Tadalafil; Wnt Signaling Pathway | 2013 |